arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Amgen Inc.

AMGN Health Care Biotechnology: Biological Products (No Diagnostic Substances)
$447.28
▲ +1.9% Today
as of Oct 22, 16:45 ET
Last 30 days +17.24% Sep 14 → Oct 22
$369.92 $390.69 $411.46 $432.24 $453.01 Sep 14 Sep 22 Sep 29 Oct 07 Oct 14 Oct 22
Open
$441.55
High
$450.98
Low
$437.19
Volume
$3M
Avg Vol
$3M
Mkt Cap
$223.3B
P/E (TTM)
31.71
Beta
—
52w High
$450.98
52w Low
$288.00
Div Yield
—
Shares Out
$541M

Recent Press Releases & News last 60 days · 25 items

mixed ▲ 0 ● 25 ▼ 0
Oct 21 · 17:30 Insider Monkey neutral
Amgen (AMGN) Sales Grew 10%, but Can Earnings Catch Up to the Price?
Oct 21 · 17:06 Trefis neutral
What Changed In Amgen's Story?
Oct 21 · 10:43 Clinical Trials Arena neutral
Amgen and AstraZeneca report Phase III Tezspire data for EoE
▸ Show all 25 press releases & news Free account →

AMGN earnings at a glance

Amgen Inc. (AMGN) is scheduled to report earnings on Tuesday, November 3, 2026 — in 11 days. Analysts expect earnings per share of $5.69, compared with $5.64 in the same quarter last year (+1%). The options market is pricing a move of about ±1.5% after the report, a range of roughly $440.39 to $454.17 from today's $447.28. Over its last 6 reports the stock rose the next day 3 times and fell 3, moving ±5.2% on average; after the most recent report on Aug 4, 2026 it moved +4.6%. That means options currently expect less movement than AMGN has typically delivered. AMGN beat the consensus EPS estimate in 6 of its last 6 reported quarters. Implied volatility is currently 37%. The share price of $447.28 sits near its 52-week high.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$288
$451
98% of range
Avg surprise (last 6)
+12.9%
Avg reaction (last 6)
+1.6%
50% positive
Latest IV / EM
37%
EM ±1.5% · $408 · Oct 9

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.21$1.42$3.04$4.67$6.29 Actual $5.28Actual $2.57Actual $3.22Actual $-0.21Actual $1.38Actual $5.22Actual $4.90Est $4.16Actual $6.02Est $5.26Actual $5.64Est $5.00Actual $5.29Est $4.76Actual $5.15Est $4.73Actual $6.29Est $5.60 MarJunSepMarJunSepMar/2025Jun/2025Sep/20258K8KJun/2026
Revenue vs Net Income Revenue Net income
$0$2.6B$5.3B$7.9B$10.6B Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Aug 4, 2026Jun/2026 $6.29 $5.60 +12.3% -7.0% +4.6% earnings
Thu Apr 30, 20268K 2026-04-30 $5.15 $4.73 +8.9% — -4.7% earnings
Tue Feb 3, 20268K 2026-02-03 $5.29 $4.76 +11.1% — +8.2% earnings
Tue Nov 4, 2025Sep/2025 $5.64 $5.00 +12.8% — +7.8% earnings
Tue Aug 5, 2025Jun/2025 $6.02 $5.26 +14.4% — -5.1% earnings
Thu May 1, 2025Mar/2025 $4.90 $4.16 +17.8% — -0.9% earnings
Mon Sep 30, 2024Sep 2024 $5.22 — — — — financials
Sun Jun 30, 2024Jun 2024 $1.38 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.21 — — — — financials
Sat Sep 30, 2023Sep 2023 $3.22 — — — — financials
Fri Jun 30, 2023Jun 2023 $2.57 — — — — financials
Fri Mar 31, 2023Mar 2023 $5.28 — — — — financials

Upcoming

DateFiscalTimeEPS EstLY EPSYoY %Δ
Tue Nov 3, 2026Sep/2026OTHER $5.69$5.64 +0.9%

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$10.05B$8.62B—$9.56B$9.18B$8.15B—$8.50B
Cost of revenue$2.81B$2.74B—$3.08B$3.01B$2.97B—$3.31B
Gross profit————————
Operating income$3.51B$2.67B—$2.53B$2.66B$1.18B—$2.05B
Net income$2.38B$1.82B—$3.22B$1.43B$1.73B—$2.83B
EPS (diluted)$4.37$3.34—$5.93$2.65$3.20—$5.22

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$13.99B$12.04B$9.13B$9.45B$8.03B$8.81B$11.97B$9.01B
Inventory$6.22B$6.19B$6.22B$6.35B$6.58B$6.73B$7.00B$7.36B
Total current assets$34.96B$31.48B$29.06B$27.89B$26.73B$26.93B$29.03B$26.77B
Total assets$95.64B$92.50B$90.59B$90.14B$87.90B$89.37B$91.84B$90.88B
Long-term debt$51.86B$51.89B$50.01B$52.43B$53.76B$54.01B$56.55B$56.85B
Total liabilities————————
Total equity$11.69B$9.19B$8.66B$9.62B$7.43B$6.21B$5.88B$7.53B

Implied volatility — last 90 days

23%34%45%56%66% Jun 07 — IV 32% · EM ±3.0%Jun 08 — IV 32% · EM ±2.7%Jun 09 — IV 32% · EM ±2.3%Jun 10 — IV 33% · EM ±1.9%Jun 11 — IV 45% · EM ±1.9%Jun 15 — IV 31% · EM ±2.2%Jun 16 — IV 32% · EM ±1.9%Jun 17 — IV 39% · EM ±1.6%Jun 19 — IV 28% · EM ±3.1%Jun 22 — IV 31% · EM ±2.6%Jun 23 — IV 31% · EM ±2.2%Jun 24 — IV 32% · EM ±1.9%Jun 25 — IV 37% · EM ±1.6%Jun 29 — IV 27% · EM ±6.4%Jun 30 — IV 27% · EM ±6.3%Jul 01 — IV 37% · EM ±1.6%Jul 03 — IV 24% · EM ±2.6%Jul 06 — IV 31% · EM ±2.6%Jul 07 — IV 30% · EM ±2.1%Jul 08 — IV 32% · EM ±1.9%Jul 09 — IV 38% · EM ±1.6%Jul 13 — IV 31% · EM ±2.6%Jul 14 — IV 31% · EM ±2.2%Jul 15 — IV 37% · EM ±2.2%Jul 16 — IV 40% · EM ±1.7%Jul 20 — IV 36% · EM ±3.0%Jul 21 — IV 35% · EM ±2.5%Jul 22 — IV 36% · EM ±2.1%Jul 23 — IV 40% · EM ±1.7%Jul 27 — IV 34% · EM ±2.9%Jul 28 — IV 38% · EM ±2.7%Jul 29 — IV 39% · EM ±2.3%Jul 30 — IV 33% · EM ±1.4%Aug 03 — IV 62% · EM ±5.1%Aug 04 — IV 67% · EM ±4.8%Aug 05 — IV 40% · EM ±2.4%Aug 06 — IV 37% · EM ±1.6%Aug 10 — IV 29% · EM ±2.5%Aug 11 — IV 29% · EM ±2.1%Aug 12 — IV 28% · EM ±1.7%Aug 13 — IV 24% · EM ±1.0%Aug 17 — IV 30% · EM ±2.5%Aug 18 — IV 30% · EM ±2.2%Aug 19 — IV 41% · EM ±2.4%Aug 20 — IV 38% · EM ±1.6%Aug 24 — IV 37% · EM ±3.1%Aug 25 — IV 35% · EM ±2.6%Aug 26 — IV 37% · EM ±2.2%Aug 27 — IV 32% · EM ±1.3%Aug 31 — IV 36% · EM ±3.0%Sep 01 — IV 37% · EM ±2.7%Sep 02 — IV 36% · EM ±2.1%Sep 03 — IV 39% · EM ±1.6%Sep 07 — IV 47% · EM ±3.9%Sep 08 — IV 36% · EM ±2.6%Sep 09 — IV 31% · EM ±1.8%Sep 10 — IV 37% · EM ±1.5%Sep 14 — IV 28% · EM ±2.3%Sep 15 — IV 29% · EM ±2.1%Sep 16 — IV 26% · EM ±1.5%Sep 17 — IV 33% · EM ±1.4%Sep 21 — IV 28% · EM ±2.4%Sep 22 — IV 31% · EM ±2.3%Sep 23 — IV 35% · EM ±2.0%Sep 24 — IV 30% · EM ±1.2%Sep 28 — IV 27% · EM ±6.5%Sep 29 — IV 27% · EM ±6.3%Sep 30 — IV 31% · EM ±1.9%Oct 01 — IV 40% · EM ±1.7%Oct 06 — IV 29% · EM ±2.1%Oct 07 — IV 30% · EM ±1.7%Oct 08 — IV 37% · EM ±1.5%

Sector peers

GILD
Gilead Sciences, Inc.
$182.1B $157.19+0.4%
MRNA
Moderna, Inc.
$78.4B $202.63-16.3%
ARGX
argenx SE
$57.6B $875.76+0.7%
RVMD
Revolution Medicines, Inc.
$43.1B $187.69-4.5%
BIIB
Biogen Inc.
$32.8B $253.84+4.4%
BNTX
BioNTech SE
$23.9B $89.67-1.6%

AMGN earnings FAQ

When is AMGN's next earnings date?

Amgen Inc. is expected to report on November 3, 2026.

What is AMGN's expected move for earnings?

Options currently price a move of about ±1.5%, or $6.89 per share either way from $447.28.

How does AMGN stock usually react to earnings?

Across the last 6 reports the average next-day move was ±5.2%, up 3 times and down 3 times.

What EPS are analysts expecting from Amgen Inc.?

The consensus estimate is $5.69 per share, versus $5.64 a year ago.

What is AMGN's implied volatility?

AMGN's at-the-money implied volatility is about 37% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in